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SuMMARY – Triple-negative breast cancer (TNBC) occurs in around one-sixth of all breast 
cancer (BC) patients, with the most aggressive behavior and worst prognosis of all BC subtypes. It is 
a heterogeneous disease, with specific molecular characteristics and natural dynamics of early recur-
rence and fast progression. Due to the lack of biomarkers or any valid treatment targets, it can only be 
treated with classic cytotoxic chemotherapy. We analyzed a cohort of 152 patients, median age 58 
years, diagnosed with and treated for early stage TNBC at the university Hospital for Tumors, Sestre 
milosrdnice university Hospital Centre, Zagreb, Croatia, during the 2009-2012 period. Patients were 
treated with primary surgical approach, adjuvant chemotherapy and adjuvant irradiation. We observed 
a relatively large proportion of locally advanced TNBC at diagnosis, with large tumor size and nodal 
involvement, with high grade and high proliferation index Ki67. Patient age, tumor size and lymph 
node involvement, as expected, were significant and clinically most important prognostic factors for 
5-year disease-free survival (67%; 95% CI 60%-75%) and overall absolute survival rate (74%; 95% CI 
66%-81%).
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Introduction
Molecular profiling has shown that breast cancer 
(BC) is a heterogeneous disease. According to gene 
expression, there are four essential, intrinsic subtypes 
of BC: luminal A (LA), luminal B (LB), HER2 en-
riched, and basal-like type1. The goal of classifying BC 
is to better understand the biology and to identify bio-
markers for therapeutic decision. In practice, we use 
immunostaining to detect three biomarkers, ER, PR 
and HER2, at protein level. Based on their expression, 
as well as expression of Ki67, we use surrogate sub-
types to guide our therapeutic decision, as follows: lu-
minal A-like, luminal B-like (HER2 positive and 
HER2 negative), nonluminal HER2 positive, and tri-
ple-negative BC (TNBC). These are four prognosti-
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cally different entities, diseases that behave differently, 
respond differently to therapy, and have different sur-
vival outcome2, with luminal subtypes, especially lumi-
nal A being the subtype with indolent disease and 
good outcome, and the TNBC subtype with very few 
therapeutic options and poor outcome3. Histologically, 
TNBC is in most cases invasive ductal carcinoma but 
may also be one of the rarer histologic subtypes such as 
apocrine or adenoid cystic, with better prognosis4. 
TNBC was first mentioned in the literature in 20055, 
and since then, thousands of scientific papers have 
been published covering different aspects of TNBC. 
Since it is a highly heterogeneous disease, different 
subtypes of TNBC have different genetic basis, phe-
notypic expression, different behavior, different re-
sponse to therapy and prognosis6. TNBC can be fur-
ther reclassified according to gene expression, DNA 
and RNA changes observed, expression of proteins on 
tumor cell, and immune potential7-10. One of the first 
comprehensive molecular profilings of TNBC was 
Lehmann’s categorization into six TNBC subtypes, as 
follows: basal-like 1 (BL1), basal-like 2 (BL2), mesen-
chymal (M), mesenchymal stem-like (MSL), luminal 
AR type (LAR), and immunomodulatory type (IM)11. 
This characterization has been further modified by 
Burstein and Lehmann himself into four subtypes of 
TNBC, i.e. two basal-like types, immunoactivated and 
immunosuppressed, mesenchymal and luminal andro-
gen receptor (LAR) type12,13. In practice, TNBC and 
basal-like BC are often considered synonyms for the 
same entity, but based on the scientific data available, 
there is a substantial but not complete overlap14-16. 
TNBC occurs in about 12%-17% of BC, most com-
monly in younger women, often BRCA mutation car-
riers, or sporadically, and is characterized by aggressive 
nature17. Epigenetic changes are also often present in 
the BRCA genes of sporadically developed, nonhe-
reditary TNBC18. TNBC are mostly poorly differenti-
ated tumors of high mitotic index, more often involv-
ing lymph nodes and lymphovascular spaces, and 
growing faster. Due to these aggressive characteristics, 
they are more sensitive to chemotherapy and evidently 
respond better compared to other BC subtypes3,19-21. 
However, despite better initial responses to therapy re-
ported, the end outcomes in treating TNBC are much 
worse than in other BC subtypes, a phenomenon 
known as the ‘TNBC paradox’22.TNBC is character-
ized by aggressive behavior including high metastatic 
potential, higher rates of local and distant disease re-
currence, a particular tendency to deliver distant, vis-
ceral metastases, most commonly to the lungs and 
brain, rapid progression and short time from the ap-
pearance of distant metastases to death19,20. The de-
scribed dynamics of TNBC has been observed within 
the first 3 to 5 years of the diagnosis, after which the 
risk of disease recurrence and the rate of return and 
dissemination of disease are equated with those ob-
served in other BC subtypes, which have a lower and 
more uniform risk of disease recurrence over a longer 
period of time23. There is no effect of endocrine thera-
py or targeted anti-HER2 therapy in TNBC. The 
backbone of TNBC treatment is still classic cytotoxic 
therapy. The optimal chemotherapy approach to 
TNBC has not been defined and the treatment prin-
ciples used in other types of BC are also used in 
TNBC, with the fact that TNBC is much more likely 
to have more risk factors present that influence thera-
peutic decision24. TNBC shows high rates of patho-
logic complete response (pCR) to neoadjuvant che-
motherapy (NAT), and when pCR is achieved, the 
long-term overall survival (OS) is often good. How-
ever, in cases where pCR is not achieved, the prognosis 
of TNBC is very poor and significantly worse than in 
other types of BC21,25. In systemic approach, chemo-
therapy based on anthracyclines and taxanes is most 
commonly used26,27, and the use of other drugs such as 
platinum compounds has been shown to be effective, 
especially in the treatment of BRCA mutated 
TNBC26,28. Capecitabine is also often used as adjuvant 
treatment, if NAT failed to provide pCR29. In addition 
to conventional cytotoxic therapy, some targeted ther-
apies have also been attempted, and poly(ADP-ribose) 
polymerase (PARP) inhibitors are showing very en-
couraging results in metastatic setting30-33. A certain 
proportion of TNBC express androgen receptors, which 
are an attractive therapeutic target34. In recent years, 
there has been a growing interest in the immunogenic-
ity of TNBC and immunotherapy as a new, potentially 
successful therapeutic approach. Data in the metastat-
ic setting are strongly proposing survival impact35, and 
the lately results of neoadjuvant experience also direct 
the interest towards the immunologic arsenal36.
The primary objective of our study was to identify 
the prognostic factors associated with TNBC out-
come. Secondary objectives were to describe the char-
acteristics of TNBC, its treatment and treatment out-
comes in real-world clinical practice, based on a single 
institution experience.
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Patients and Methods
Study design
We conducted this observational, real-world, sin-
gle-center, retrospective cohort study at the university 
Hospital for Tumors, Sestre milosrdnice university 
Hospital Centre, Zagreb, Croatia, with 5-year follow-
up, on a consecutive sample of all women diagnosed 
with and treated for early TNBC from January 1, 2009 
to December 31, 2012. The study protocol was ap-
proved by the Ethics Committee of the Sestre mi-
losrdnice university Hospital Centre and Ethics 
Committee of the School of Medicine, university of 
Zagreb. The study was conducted in accordance with 
all applicable guidelines and rules, including the World 
Health Organization Helsinki Declaration of 1975, as 
amended in 201329,37, the Health Care Act of the Re-
public of Croatia and the Patient Rights Act of the 
Republic of Croatia. The identity of patients was only 
known to the principal investigator, and identity data 
were not collected or recorded.
Target population
The target population included patients diagnosed 
with early TNBC. The diagnosis of TNBC was made 
by analysis of tumor tissue specimens treated with a 
standard histopathologic method involving tissue fixa-
tion in 10% buffered formalin and paraffin embedding 
(FFPE specimens), with an immunohistochemically 
proven negative reaction to ER/PR and HER2 status. 
Patients whose samples were in accordance with the 
current American Society of Clinical Oncology/Col-
lege of American Pathologists (ASCO/CAP) recom-
mendations for HR and HER2 testing were included 
in the analysis27,28,38,39 . The triple negative tumor was 
therefore defined by ER/PR <1% and negative HER2 
(immunohistochemistry (IHC) 0 and 1+ and IHC 2+ 
but in situ hybridization (ISH) negative). Inclusion 
criteria were age ≥18 years, patient diagnosed with 
early TNBC without other malignancies (excluding 
basal cell skin cancer), histopathologic confirmation of 
TNBC, and clinical and radiological confirmation of 
early stage disease. Exclusion criteria were diagnosis of 
other malignant tumor, BC recurrence, advanced 
(metastatic) disease, bilateral BC regardless of the dis-
ease biology, multiple BC if the focal points of the tu-
mor had proven different biology, and male sex.
Sample type and sample size required
The minimum sample size required was calculated 
before data collection for the primary objective with 
the following assumptions: statistical significance level 
p<0.05, targeted statistical power of 80%, eight prog-
nostic factors (age, menopausal status, comorbidities, 
histologic type, tumor size, number of positive lymph 
nodes and grade, all measured at the time of diagno-
sis), and minimum partial coefficient of determination 
considered clinically relevant R2 ≥0.10. under these as-
sumptions, a sample size of 144 patients was finally 
required. Given the retrospective nature of the study, 
we expected that ≤15% of patients would have missing 
data on the primary outcome and at least one of the 
eight prognostic factors. Therefore, we decided to in-
crease the number of enrolled patients to 170.
Outcomes
The primary outcome was the 5-year absolute sur-
vival rate defined as the percentage of patients who 
were alive after 5 years of primary surgery. The first 
secondary outcome was the OS defined as the time in 
months from primary surgery to death from any cause. 
OS data on patients who were alive after five years 
were censored at the time of their last visit. The second 
secondary outcome was the 5-year disease-free sur-
vival (DFS) rate defined as the percentage of patients 
with no disease recurrence or death after 5 years of 
primary surgery. The third secondary outcome was 
DFS defined as the time in months without any signs 
or symptoms of TNBC from surgery to disease recur-
rence or death from any cause. DFS data on patients 
with no disease recurrence were censored at the time 
of their last visit.
Prognostic factors
We defined prognostic factors as the tumor and pa-
tient characteristics the value of which at the time of 
diagnosis was associated with the natural course of 
TNBC or outcome of the standard treatment. Clini-
cal, sociodemographic and histopathologic possible 
prognostic factors that we assessed for our primary ob-
jective were age in years, menopausal status confirmed 
by physician, presence of any comorbidity recorded in 
the hospital electronic medical records, tumor histo-
logic type dichotomized into ductal carcinoma or oth-
er, tumor size measured in millimeters, number of 
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Table 1. Patient characteristics at diagnosis (N=152)
n (%)
Age (years), median (IQR) 58 (47-70)
Menopause 98 (64.5)
Comorbidities* 89 (61.0)
Cancer in family† 39 (35.5)
Breast cancer in family† 18 (16.5)
Histopathology:
 Ductal carcinoma (NOS) 128 (84.2)
 Lobular carcinoma 1 (0.7)
 Medullary carcinoma 14 (9.21)
 Apocrine carcinoma 4 (2.63)
 Other 5 (3.29)
Tumor size (cm), median (IQR) 2.2 (1.55-2.95)
 T1 57 (37.5)
 T2 83 (54.6)
 T3 12 (7.9)
Lymph nodes
 N0 90 (59.2)
 N1 35 (23.0)
 N2 12 (7.9)
 N3 15 (9.9)
Lymph nodes examined, median 
(IQR) 16 (12-20)
Lymph nodes positive 62 (40.8)
Grade
 I 3 (2.0)
 II 25 (16.5)
 III 124 (81.6)
Ki-67, median (IQR) 57 (29-77)
 Ki67 <20 23 (15.1)
 Ki67 ≥20 129 (84.9)
Data are presented as number (percentage) of patients, if not speci-
fied otherwise; IQR = interquartile range; NOS = not otherwise 
specified; *data were missing for comorbidities in 6 (3.9%) patients; 
†due to too much data missing, family history was not included in 
analysis: cancer in family 42 (27.6%) data missing, breast cancer in 
family 43 (28.3%) data missing.
positive lymph nodes, histologic tumor grade, and pro-
liferative index Ki67.
Other descriptive variables
Additional variables we used to describe the char-
acteristics of TNBC and standard treatment were self-
reported family history, surgical treatment applied, 
lymph node dissection, adjuvant systemic treatment, 
type of chemotherapy administered, and adjuvant ir-
radiation.
Statistical analysis
We performed primary analysis of the 5-year abso-
lute survival rate using the multivariable binary logistic 
regression with all eight possible prognostic factors en-
tered simultaneously. In the introductory series of bi-
variable binary logistic regressions, we analyzed meno-
pausal status as well, but we excluded it from the main 
analysis to prevent the multicollinearity with age. We 
repeated primary analysis with age excluded and meno-
pausal status included. In presentation of the logistic 
regression results, we presented odds ratios (OR) with 
their 95% confidence intervals (CI), statistical signifi-
cance, and the false discovery rate (FDR). We described 
secondary outcomes, OS and DFS using Kaplan-Mei-
er curves with 95% CI. Data on comorbidities were 
missing in six (3.9%) patients. For multivariable analy-
ses we imputed the missing data using multiple impu-
tation with Markov Chain Monte Carlo procedures, 
data augmentation algorithm. We set the seed at 
374823 to enable replication of multiple imputations 
and did 20 imputations using all possible prognostic 
factors as predictors. Due to the large number of miss-
ing data, we did not use positive family history for any 
cancer and for BC, and body mass index. We controlled 
the false positive finding rate using the Benjamini-Ho-
chberg procedure with FDR <10%. We set the level of 
two-tailed statistical significance at p<0.05 and all CI 
at 95%. Statistical analysis was performed using the 
StataCorp. 2019 Stata Statistical Software: Release 16 
(StataCorp LLC, College Station, TX, uSA).
Results
Sociodemographic and clinical characteristics  
of TNBC patients
We enrolled 152 patients aged 26-85, median 
(IQR) age 58 (47-70) years (Table 1), just over two-
thirds of them menopausal. In routine medical records, 
family history data were lacking in a high percentage 
of cases, i.e. 42 (27.6%) for any cancer and 43 (28.3%) 
for BC. We kept these data in descriptive Table 1, but 
did not interpret them. In patients for whom we had 
properly collected data, 18/109 (16.5%) had a positive 
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family history of BC. Patients with a positive family 
history of BC were younger, median (IQR) age 43 
(38-54) years compared to patients without family 
BC, median (IQR) age 57 (47-69) years. The vast ma-
jority of patients had ductal invasive carcinoma with a 
median (IQR) tumor size of 2.2 (1.55-2.95) cm, 62 
(40.8%) with positive lymph nodes, 124 (81.6%) with 
grade III tumor, and median (IQR) Ki67 proliferation 
index 57 (29-77). Just over one-third of patients un-
derwent radical surgery (Table 2), and almost all of 
them underwent axillary dissection. Adjuvant chemo-
therapy was used in 130/148 (87.8%) patients, in 
114/128 (89.1%) cases with anthracyclines or a combi-
nation of anthracyclines and taxanes. A total of 
103/140 (73.6%) patients were treated with adjuvant 
radiotherapy. None of the patients was treated with the 
neoadjuvant approach.
Treatment outcomes
During the 5-year follow-up from BC surgery, 
50/151 (32.9%; 95% CI 25.5-41.0%) patients experi-
enced disease recurrence or death, and 40/152 (26.3%; 
95% CI 19.5-34.1%) died. Thus, the overall 5-year ab-
solute survival rate was 112/152 (73.7%; 95% CI 65.9-
80.5%). At the last examination, 102/152 (67.1%; 95% 
CI 59.6-74.7%) patients were alive and with no dis-
ease, so the median DFS was not reached during the 
5-year follow-up (Fig. 1). The lower quartile (25th per-
centile) of DFS was 60 months. The arithmetic mean 
of DFS was 48 (95% CI 45-51) months. Median 
(IQR) OS was not reached at five-year follow-up (Fig. 
2). The lower quartile (25th percentile) of OS was 54 
Table 2. Treatment approach (N=152)
n (%)
Type of surgery:
 Conservative 93 (61.2)
 Radical 59 (38.8)
Axillary dissection 150 (98.7)
Adjuvant chemotherapy 131 (88.5)
Type of chemotherapy:
 Anthracyclines 71 (55.5)
 Anthracyclines and taxanes 43 (33.6)
 CMF 11 (8.6)
 Taxanes only 1 (0.8)
 Other 2 (1.6)
Adjuvant radiotherapy 103 (73.6)
CMF = cyclophosphamide-methotrexate-5-fluorouracil; data were 
missing for adjuvant chemotherapy in 4 (2.6%) and type of chemo-
therapy in 3 (2.3%) out of 131 patients treated with adjuvant che-
motherapy; and for adjuvant radiotherapy in 12 (7.9%) patients.
Fig. 1. Kaplan-Meier curve of survival without disease recurrence or death in months  
from surgery (N=152).
DFS = disease free survival; CI = confidence interval
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months. The arithmetic mean of OS was 51 (95% CI 
48-54) months.
Prognostic factors
After adjustment for all other possible prognostic 
factors using the multivariable binary logistic regression, 
the absolute 5-year survival rate was significantly associ-
ated with age (OR=0.95; 95% CI 0.92-0.99; p=0.007; 
FDR <10%), tumor size (OR=0.65; 95% CI 0.48-0.88; 
p=0.006; FDR <10%), and number of positive lymph 
nodes (OR=0.78; 95% CI 0.67-0.90; p=0.001; FDR 
<10%) (Table 3). Older age, larger tumor size and more 
positive axillary lymph nodes were associated with 
worse prognosis. In repeated multivariable analysis with 
age excluded and menopausal status included, meno-
pausal status was not the independent significant prog-
nostic factor for the absolute 5-year survival rate 
(OR=0.74; 95% CI 0.27-2.02; p=0.552; FDR >10%).
Discussion
This paper presents the retrospective cohort study 
in 152 patients diagnosed with and treated for early 
TNBC. We observed the significant and clinically rel-
evant prognostic value of age, tumor size and number 
of positive lymph nodes measured at the time of diag-
nosis for the 5-year absolute survival rate.
With a median age of 58 years, this cohort of pa-
tients was comparable to the cohorts in several similar 
studies in patients with early TNBC conducted in re-
cent years in the relatively close geographical areas 
(Slovenia, Italy), but also in other parts of the world 
(Canada)23,40-42. Patients younger by ten years were 
studied in India, Kuwait and Turkey43-45, which is in 
line with the well-documented fact that patients with 
TNBC from these countries are mostly younger com-
pared to other geographical areas. Accordingly, it is not 
surprising that 64% of patients in our cohort were 
postmenopausal, compared to a similar population of 
patients younger by three years in Slovenian study40 
and Italian42 studies with 60% of postmenopausal pa-
tients. Despite the large proportion of family predis-
position data, a positive family history of BC was ob-
served in about one-sixth of the patients analyzed, and 
these patients were by even 15 years younger than 
those without a positive family history were, which is 
in line with the data expected for a population of pa-
tients with hereditary predisposition for BC46. unfor-
tunately, at the time the designated cohort of patients 
was treated, there was no recommendation for BRCA 
testing to be conducted, according to risk, as encour-
aged today, yet not routinely performed, or reflex test-
ing in all TNBC patients in our country. As expected, 
the most prevalent histologic subtype of TNBC was 
Fig. 2. Kaplan-Meier survival curve in months from surgery (N=152).
OS = overall survival; CI = confidence interval
Ana Tečić Vuger et al. Triple-negative breast cancer
Acta Clin Croat, Vol. 59, No. 1, 2020 103
ductal invasive carcinoma, while the prevalence of 
medullary cancer, which, although one of the rare spe-
cial histologic subtypes of BC, is expected to be high-
est among TNBC, is also noticeable4. A similar distri-
bution was observed in other comparable studies40-42.
In our cohort, the definition of TNBC implied, in 
addition to the negative finding of HER2 (either IHC 
or ISH), IHC negative ER and PR according to the 
valid ASCO/CAP recommendations, which was <1% 
of expression38. The same pattern was used in several 
recent comparative analyses42, and differed somewhat 
from similar analyses in which a limit value of IHC 
was taken to have an ER/PR expression of 10% and 
therefore so-called borderline tumors (1%-9% IHC 
ER/PR) were analyzed as TNBC23,40,41,47. The above 
should be taken into account when interpreting the 
results obtained, as a possible explanation for the ob-
served differences in the cohorts compared38,48. As in 
similar analyses49, our patients with early TNBC most 
often had a tumor larger than 2 cm and more than 
40% of them had positive lymph nodes already at di-
agnosis, which agrees with the known facts about 
TNBC as the most aggressive and rapidly progressing 
tumor, which gives metastases to the lymph nodes very 
early and with small primary tumors20-22,50. This was 
relativized in a study by uS authors who showed the 
Table 3. Association of 5-year absolute survival rate with sociodemographic and clinical characteristics of patients 
(N=152)
Survived Bivariable, unadjusted analysis Multivariable, adjusted analysis
n (%) OR (95% CI) p OR (95% CI) p
Age (years) n.a. 0.96 (0.94-0.99) 0.005 0.95 (0.92-0.99) 0.007
Menopause*:
 No 43 (79.6) 1
 Yes 69 (70.4) 0.61 (0.28-1.34) 0.219
Comorbidities†:
 No 45 (71.4) 1 1
 Yes 67 (75.3) 1.22 (0.59-2.52) 0.595 1.68 (0.60-4.73) 0.323
Histopathology:
 Other 19 (79.2) 1 1
 Ductal carcinoma (NOS) 93 (72.7) 0.70 (0.24-202) 0.508 0.76 (0.22-2.57) 0.657
Tumor size n.a. 0.69 (0.54-0.88) 0.003 0.65 (0.48-0.88) 0.006
Number of positive lymph nodes n.a. 0.75 (0.65-0.85) <0.001 0.78 (0.67-0.90) 0.001
Grade
 I-II 20 (71.4) 1 1
 III 92 (74.2) 1.15 (0.46-2.87) 0.764 0.74 (0.26-2.11) 0.579
Ki67 n.a. 1.01 (1.00-1.02) 0.154 1.02 (1.00-1.04) 0.083
Type of surgery:
 Conservative 81 (87.1) 1
 Radical 31 (52.5) 0.16 (0.07-0.36) <0.001
Adjuvant chemotherapy:
 None 13 (54.2) 1
 Other 5 (35.7) 0.47 (0.12-1.82) 0.275
 Anthracyclines 63 (88.7) 6.66 (2.24-19.80) 0.001
 Anthracyclines and taxanes 31 (72.1) 2.19 (0.77-6.21) 0.142
n.a. = not available; n = number of patients; OR = odds ratio; CI = confidence interval; p = statistical significance calculated using binary 
logistic regression; NOS = not otherwise specified; *data were missing for 6 (3.9%) patients and were imputed using multiple imputation; 
†menopausal status was excluded from multivariable analysis to prevent multicollinearity with age.
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least correlation of the triple-negative phenotype with 
positive lymph nodes; however, this phenomenon is 
not clearly explained51.
More than one-fifth of our patients had N2 or N3 
stage lymph nodes. These are, by definition, initially 
borderline or clearly inoperable diseases, that is, they 
describe the locally advanced disease stage (LABC) 
and imply the need for primary systemic treatment 
(neoadjuvant approach)52,53. The fact that patients in 
this cohort, from 2009 to 2012, were treated exclusive-
ly with primary surgery and then with adjuvant sys-
temic therapy and radiation, without applying a neo-
adjuvant approach despite the diagnosis of LABC, 
indicates the evolution of patient care from treatment 
times of this cohort to date, when they are known to 
have a clear indication for neoadjuvant treatment53,54. 
Patients in our cohort, as expected, and similarly ob-
served in other concordant analyses40-43,49, had a high 
tumor grade and significantly high Ki67 proliferation 
index, which also confirms the more aggressive nature 
of TNBC compared to other BC subtypes. As men-
tioned above, patients, unlike today’s treatment ap-
proach, with a higher proportion of neoadjuvant access 
were treated exclusively with breast surgery, axillary 
dissection in almost all of them, and then adjuvant 
chemotherapy and radiotherapy. In contrast to over 
80% of mastectomies reported in the Chinese analy-
sis48, in this cohort of patients, conservative surgery 
was performed in more than 60% of cases, although 
not followed accordingly with sentinel lymph node bi-
opsy for axillary staging and also possible definitive 
treatment, according to today’s standard practice in 
low risk cases54, but rather with axillary dissection in 
almost all cases. Although in some comparable analy-
ses, the percentage of conservative surgery was similar 
to ours43 , there was a marked difference between co-
horts according to disease stage at diagnosis (signifi-
cantly more LABC in our cohort, possibly also due to 
implementation of the national screening program just 
shortly before the designated cohort of patients was 
treated, meaning having only first cycle of mammog-
raphy screening program passed, before this popula-
tion of patients), thus justifying the conservative ap-
proach in those cohorts. Considering the previously 
mentioned fact of not using the neoadjuvant treatment 
approach, and the significant number of LABCs at di-
agnosis in our cohort of patients, this is certainly not a 
reflection of criticality, from today’s perspective, how-
ever, it is a reflection of the standard of care in the ana-
lyzed period. Chemotherapy was most often based on 
anthracyclines and taxanes, which to this day remain 
the standard choice for the systemic treatment of more 
aggressive BC subtypes54,55.
The overall absolute 5-year survival rate in our 
study was strikingly similar to the one observed in the 
Slovenian41 and Italian43 studies, markedly lower than 
in the Chinese one48, where 89% of patients were alive 
after five years, and markedly better than the Indian 
cohort analyzed during the similar period, with a re-
ported 3-year OS of 66%44. Similar survival results in 
our cohort to those reported by Slovenian and Italian 
authors can also partially be interpreted by similar 
characteristics of patients living in the close geograph-
ical area, and by the similar treatments used, i.e. similar 
use of operative treatment, radiation and chemothera-
py. Likewise, the reason for better OS compared to the 
Chinese study may also be partially interpreted by the 
fact that these patients had less advanced disease (stag-
es I and II >70%) and more radical treatment (mastec-
tomy >80%). The Indian cohort of patients observed 
during the same period as ours had a larger primary 
tumor in a larger number of patients (89% of patients 
with tumor >2 cm) and almost 60% of cases of positive 
lymph nodes. Patients in our cohort experienced dis-
ease recurrence or death similar to the Slovenian (32%) 
and Italian (33% after 4.3-year follow-up) cohorts of 
patients40,42.
As expected, the most significant prognostic fac-
tors were age, tumor size, and positive lymph 
nodes53,55,56. As in the other studies mentioned, the 
higher the tumor size and the more lymph nodes af-
fected, indicating a more advanced stage of the disease, 
the worse is the prognosis40-45,47. In contrast to our re-
sults, where younger patients had higher odds for dis-
ease recurrence and death, which is consistent with the 
known facts about greater aggression of the disease at 
a younger age and probably different essential biology 
than the disease in the older population, in the Slove-
nian study older patients had a higher risk, which is 
also explained by the fact that a much smaller percent-
age of older patients are treated with adjuvant chemo-
therapy40. The Ki67 proliferation index proportionally 
increased the risk of disease recurrence and death, once 
again indirectly pointing to the described TNBC par-
adox23, where more aggressive tumors with a signifi-
cant degree of high cell proliferation are expected to be 
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more chemosensitive; however, because of its marked 
and large percentage of local and especially distant dis-
ease recurrences have worse survival rates.
Limitations of the study
The first limitation of our description of TNBC 
characteristics was its possible lower generalizability 
(external validity) caused by the fact, as already ex-
plained, that at the time of observation neoadjuvant 
chemotherapy was not a standard procedure in our in-
stitution. It is likely that the absolute 5-year survival 
rates in the currently treated patients are better than 
the ones we observed. As the neoadjuvant chemother-
apy may have affected both the tumor size and the pri-
mary and adjuvant treatment outcomes, it is possible 
that the role of this and other prognostic factors would 
be different after the neoadjuvant treatment. It was not 
possible to estimate the extent of this lowering of ex-
ternal validity. Another threat to the generalizability 
was probably caused by the fact that we observed the 
cohort diagnosed and treated in a single center. It is 
not impossible that the standard treatment and/or 
even patient characteristics, and consequently treat-
ment outcomes differ between our and other centers. 
Moreover, as the participating institution is a highly 
specialized department in country capital, it is possible 
that our catchment population is different from the 
populations in smaller, provincial hospitals, for exam-
ple, if the detection rate is better in the wealthier, bet-
ter-educated and more urbanized country capital. Fur-
thermore, this opened our study to the selection and 
referral biases as well. The second limitation was inher-
ent to the retrospective cohort design with the hospital 
medical records as the main data source, i.e. a large 
proportion of missing data on some potentially impor-
tant prognostic factors, which prevented us from ana-
lyzing them. If we were able to include, for example, 
body mass index, it may be that some of the presented 
results of the multivariable, adjusted analysis would be 
different. The third limitation was the absence of a 
comparator, thus some of our findings may not be 
TNBC specific. Although the real setting, together 
with a proper statistical power and long-enough fol-
low-up, was probably the main strong point of our 
study, at the same time the absence of patient random-
ization to different therapeutic regimens might have 
resulted in lower internal validity of our findings on 
the importance of particular prognostic factors, par-
ticularly those that are highly associated with treat-
ment decisions. It is just not possible to reliably dif-
ferentiate prognostic from the predictive role of any 
factor without the randomized controlled design.
Conclusions
In this analysis of early TNBC patient cohort, we 
observed a relatively large proportion of locally ad-
vanced TNBC at diagnosis, with large tumor size and 
nodal involvement, high grade and high Ki67. Patient 
age, tumor size and lymph node involvement, as ex-
pected, were significant and clinically most important 
prognostic factors for 5-year DFS and OS. Observed 
characteristics of patients with early TNBC in this co-
hort were mostly expected and reported in similar 
studies, which in global reminds of the need for early 
detection and further encourages national BC screen-
ing programs. The observation that, although in a great 
percentage locally advanced cancer, there was no neo-
adjuvant approach conducted in this cohort, points to 
the fact that there has been a clear shift from that time 
to the present, from the adjuvant to neoadjuvant ap-
proach in TNBC, following the enlargement of ro-
bustness of data to the benefits of primary systemic 
treatment in TNBC. The expected poorer survival of 
patients with TNBC, taking into account all those fac-
tors, from clinical, sociodemographic and histopatho-
logic to therapeutic, reaffirms the previously noted 
need to further search for a solution for this group of 
patients, beyond current therapeutic standards in terms 
of adjustment for surgical treatment and choice of 
chemotherapy. One of the most promising ways is the 
search for new therapeutic targets, and some newly di-
agnosed biomarkers within TNBC will definitely open 
arena for new treatment options.
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Sažetak
KARAKTERISTIKE I PROGNOZA BOLESNICA S TROSTRuKO NEGATIVNIM RAKOM DOJKE:  
HRVATSKA MONOINSTITuCIJSKA RETROSPEKTIVNA KOHORTNA STuDIJA
A. Tečić Vuger, R. Šeparović, Lj. Vazdar, M. Pavlović, P. Lepetić, S. Šitić, Ž. Bajić, B. Šarčević i D. Vrbanec
Trostruko negativni rak dojke (TNRD) javlja se u oko šestine svih bolesnica s rakom dojke, s najagresivnijim ponašanjem 
i najgorom prognozom od svih podtipova raka dojke. To je heterogena bolest sa specifičnim molekularnim karakteristikama 
i prirodnom dinamikom ranog povrata i brze progresije bolesti. Zbog nedostatka biobiljega ili bilo kakvog uporabljivog 
 terapijskog cilja temelj liječenja i dalje je klasična citotoksična kemoterapija. Analizirali smo kohortu od 152 bolesnice, me-
dijan dobi 58 godina, dijagnosticirane i liječene od ranog TNRD u Klinici za tumore Kliničkoga bolničkog centra Sestre 
milosrdnice u Zagrebu, Hrvatska u razdoblju od 2009. do 2012. godine. Bolesnice su liječene primarno kirurškim pristupom, 
adjuvantnom kemoterapijom i adjuvantnim zračenjem. Zamijetili smo relativno velik udio lokalno uznapredovalog stadija 
TNRD pri dijagnozi, s velikom veličinom tumora i zahvaćanjem limfnih čvorova, visokim gradusom i visokim proliferacij-
skim indeksom Ki 67. Dob bolesnica, veličina tumora i zahvaćenost limfnih čvorova, očekivano, pokazali su se statistički 
značajnim i klinički najvažnijim prognostičkim čimbenicima petogodišnjeg preživljenja bez bolesti (67%; 95% CI 60-75%) i 
stope sveukupnog preživljenja (74%; 95% CI 66-81%).
Ključne riječi: Trostruko negativni rak dojke; Rani rak; Adjuvantno liječenje; Veličina tumora; Limfni čvor; Preživljenje bez 
bolesti; Sveukupno preživljenje; Prognostički čimbenik
